ViewsML, a Perago company specializing in the virtualization of immunohistochemistry, has just announced their achievement in securing $4.9 Million in a seed funding round led by Wittington Ventures with support from new and repeating investors like Mayo Clinic and RiSC Capital, respectively. 

Their funding win  reflects the investment community’s confidence in ViewsML’s goal to be the world’s first AI biomarker library to generate per-cell biomarker insights without the need for laboratory staining. 

“We’re building the computational layer for next-generation diagnostics, and are excited to partner with Wittington Ventures and work with Mayo Clinic to accelerate that vision. This capital will enable us to fast-track our efforts to revolutionize immunohistochemistry (IHC). By building the world’s first virtual biomarker library, we’re going to empower scientists and clinicians to analyze biomarker staining in minutes rather than the traditional days or weeks.”

Views ML CEO, Kenneth To

Read more about Views ML’s new funding partnership here:

• https://www.viewsml.com/viewsml-secures-funding-accelerate-commercialization-ai-driven-virtual-biomarker-staining-platform
• https://betakit.com/viewsml-secures-4-9-million-to-help-scientists-virtually-analyze-tissue-samples/
• https://techcouver.com/2026/04/21/viewsml-capital-build-computational-layer-diagnostics/